Showing 828 results
-
Media Release /• Data from FREEDOMS study show Gilenya reduced relapses in patients who discontinued another MS therapy due to side effects or inadequate efficacy• Analyses of five clinical studies show Gilenya,…
-
Media Release /- "Together in MS" partners professional cycling team members with people living with MS for Bike MS rides on tandem bicycles across the country- Phil Keoghan, MS advocate and TV host, rides tandem…
-
Media Release /-Tobramycin inhalation powder (TIP) recommended for management of cystic fibrosis (CF) patients six years and older with P. aeruginosa bacteria in their lungs-P. aeruginosa (Pa) is the leading cause…
-
Media Release /-- Approval based on efficacy and safety demonstrated in long-term study comparing 13.3 mg/24 h to 9.5 mg/24 h in declining mild to moderate Alzheimer's patients-- New higher dose of Exelon Patch…
-
Media Release /The initiative aims to help close diagnosis gap for Hispanic Americans by providing in-language information and resources focused on Alzheimer’s diseaseThe company will work with Univision to help…
-
Media Release /RELAX-AHF study met one of its two primary endpoints in reducing dyspnea or shortness of breath, and was therefore positive under pre-specified criteriaNewly presented data show that at six months,…
-
Media Release /- Leeza and family share highs, lows and insights about caring for her mother with Alzheimer's disease in new video series- Ten national contest winners recognized for words of wisdom about finding…
-
Media Release /La iniciativa busca ayudar a cerrar la brecha del diagnóstico de los hispanos a través de recursos e información en español sobre la enfermedad de Alzheimer La compañía trabajará junto a Univision…
-
Media Release /- Endpoints met in two Phase III trials, including substantial symptom relief in 84% of systemic juvenile idiopathic arthritis (SJIA) patients treated with ACZ885 in trial-11- SJIA patients treated…
-
Media Release /- As the only pituitary-directed therapy, Signifor represents a novel therapeutic approach by addressing the underlying mechanism of Cushing's disease(1)- In the Phase III trial, most patients…
